

MAHONEY DAVID L

Form 4/A

July 20, 2017

FORM 4**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

Check this box
if no longer
subject to
Section 16.
Form 4 or
Form 5
obligations
may continue.
See Instruction
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB
Number: 3235-0287
Expires: January 31,
2005
Estimated average
burden hours per
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *
MAHONEY DAVID L

(Last) (First) (Middle)

C/O CORCEPT THERAPEUTICS
INCORPORATED, 149
COMMONWEALTH DRIVE

(Street)

MENLO PARK, CA 94025

(City) (State) (Zip)

2. Issuer Name **and** Ticker or Trading
Symbol

CORCEPT THERAPEUTICS INC
[CORT]

3. Date of Earliest Transaction
(Month/Day/Year)
07/12/2017

4. If Amendment, Date Original
Filed(Month/Day/Year)
07/14/2017

5. Relationship of Reporting Person(s) to
Issuer

(Check all applicable)

☒ Director ☐ 10% Owner
☐ Officer (give title below) ☐ Other (specify below)

6. Individual or Joint/Group Filing(Check
Applicable Line)
☒ Form filed by One Reporting Person
☐ Form filed by More than One Reporting
Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	07/12/2017		M ⁽¹⁾	6,510 A	\$ 2.23 1,142,183	I	Held by David L. Mahoney and Winnifred C. Ellis 1998 Family Trust
	07/12/2017		S ⁽¹⁾	6,510 D	\$ 12.5 1,135,673	I	

Common
StockHeld by
David L.
Mahoney
and
Winnifred
C. Ellis
1998
Family
TrustCommon
Stock

07/13/2017

M⁽¹⁾

484

A

\$ 2.23

1,136,157

I

Held by
David L.
Mahoney
and
Winnifred
C. Ellis
1998
Family
TrustCommon
Stock

07/13/2017

S⁽¹⁾

484

D

\$
12.548
⁽²⁾

1,135,673

I

Held by
David L.
Mahoney
and
Winnifred
C. Ellis
1998
Family
Trust

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of
information contained in this form are not
required to respond unless the form
displays a currently valid OMB control
number.**SEC 1474
(9-02)**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. De Sec (In	
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Stock Option (Right to Buy)	\$ 2.23	07/12/2017	M ⁽¹⁾	6,510	⁽³⁾	06/09/2018	Common Stock	6,510
Stock Option (Right to Buy)	\$ 2.23	07/13/2017	M ⁽¹⁾	484	⁽³⁾	06/09/2018	Common Stock	484

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
MAHONEY DAVID L C/O CORCEPT THERAPEUTICS INCORPORATED 149 COMMONWEALTH DRIVE MENLO PARK, CA 94025	X			

Signatures

/s/ G. Charles Robb, Attorney-in-Fact for David L.
Mahoney

07/20/2017

 Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) These transactions are made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares.

(2) Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from \$12.52 to \$12.56 per share. Detailed information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.

(3) Fully exercisable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.